enGene Therapeutics Inc.

enGene Holdings Inc. is a clinical-stage biotechnology company focused on genetic medicine. The company aims to deliver therapeutics to mucosal tissues and other organs to address diseases with significant clinical needs, initially focusing on non-muscle invasive bladder cancer (NMIBC). enGene develops non-viral genetic medicines using its proprietary dually derived chitosan, or "DDX", gene delivery platform. This platform enables the localized delivery of complex genetic materials directly to mucosal tissues and other organs. Its primary product candidate is detalimogene voraplasmid, also known as detalimogene (formerly EG-70). This therapy is designed to foster a pro-inflammatory, anti-tumor microenvironment throughout the bladder urothelium. enGene Holdings Inc. was incorporated on April 24, 2023, as 14963148 Canada Inc. and changed its name to enGene Holdings Inc. on May 9, 2023. On October 31, 2023, the company transitioned its incorporation to be governed by the Business Corporations Act (British Columbia). On October 31, 2023, enGene Holdings Inc. completed a merger with Forbion European Acquisition Corporation ("FEAC"), a special purpose acquisition company formed on August 9, 2021. As a result, enGene Holdings Inc. became a publicly traded company, with its Common Shares and Warrants listed on the Nasdaq Global Market under the symbols "ENGN" and "ENGNW," respectively, commencing trading on November 1, 2023. enGene Inc., a subsidiary, continues the existing business operations.